Clinical Trial Detail

This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or solid organ transplants.

Ages Eligible for Study: 12 Years and older

Genders Eligible for Study: Both

- 1.Be = or>12 years of age.

- 2.Weigh = or > 40 kg.

- 3.Be a recipient of stem cell or solid organ transplantation.

- 4.Have documented CMV infection in blood or plasma, with a screening value of = or >1,000 DNA copies/mL.

- 5.Have a current CMV infection that is resistant (known CMV genetic mutations) or refractory (clinical failure to respond) to treatment with ganciclovir/valganciclovir and/or foscarnet.

- 6.If female, be either postmenopausal, surgically sterile, or have a negative pregnancy test prior to randomization.

- 7.Be able to swallow tablets.

- 8.If adult, provide written informed consent. If child (age <18 years), have a parent/legal guardian who is willing and able to provide written informed consent (with assent from the child when appropriate).

Other eligibility criteria may apply.

- 1.Be receiving any other anti-CMV agent(s).

- 2.Have a current CMV infection that is considered resistant or refractory due to inadequate adherence to prior oral anti-CMV treatment.

- 3.Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the time of enrollment.

- 4.Have severe hepatic impairment.

- 5.Require mechanical ventilation or vasopressors for hemodynamic support at the time of enrollment.

- 6.Have expected survival less than 6 weeks.

- 7.Be pregnant or breastfeeding.

- 8.Other clinically significant medical or surgical condition.

Other exclusion criteria may apply.